Page 98 - Sitomegalovirüs Tanı, Tedavi Uzlaşı Raporu

63. Green ML, Leisenring WM, Xie H, Walter RB, Mielcarek M, Sandmaier BM, et al.
CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection
in acute myeloid leukemia. Blood. 2013;122(7):1316-24.
64. Elmaagacli AH, Steckel NK, Koldehoff M, Hegerfeldt Y, Trenschel R, Ditschkowski M,
et al. Early human cytomegalovirus replication after transplantation is associated with
a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in
acute myeloid leukemia patients. Blood. 2011;118(5):1402-12.
65. Einsele H, Steidle M, Vallbracht A, Saal JG, Ehninger G, Müller CA. Early occurrence
of human cytomegalovirus infection after bone marrow transplantation as
demonstrated by the polymerase chain reaction technique. Blood. 1991;77(5):1104-
1110.
66. Boeckh M, Leisenring W, Riddell SR, et al. Late cytomegalovirus disease and
mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of
viral load and T-cell immunity. Blood. 2003;101:407-414.
67. Ljungman P, Brand R, Hoek J, de la Camara R, Cordonnier C, Einsele H, Styczynski
J, Ward KN, Cesaro S; Infectious Diseases Working Party of the European Group for
Blood and Marrow Transplantation. Donor cytomegalovirus status influences the
outcome of allogeneic stem cell transplant. Clin Infect Dis. 2014;59(4):473-81.
68. Young JH, Logan BR, Wu J, Wingard JR, Weisdorf DJ, Mudrick C, Knust K, Horowitz
MM, Confer DL, Dubberke ER, Pergam SA, Marty FM, Strasfeld LM, Brown JWM,
Langston AA, Schuster MG, Kaul DR, Martin SI, Anasetti C; Blood and Marrow
Transplant Clinical Trials Network Trial 0201. Infections after Transplantation of Bone
Marrow or Peripheral Blood Stem Cells from Unrelated Donors. Biol Blood Marrow
Transplant. 2016;22(2):359-370.
69. Hammerstrom AE, Lombardi LR, Pingali SR, Rondon G, Chen J, Milton DR, Chemaly
RF, Champlin RE, Gulbis A, Ciurea SO. Prevention of Cytomegalovirus Reactivation
in Haploidentical Stem Cell Transplantation. Biol Blood Marrow Transplant.
2018;24(2):353-358.
70. Martino R, Rovira M, Carreras E, et al. Severe infections after allogeneic peripheral
blood stem cell transplantation: a matched- pair comparison of unmanipulated and
CD34 + cell-selected transplantation. Haematologica. 2001;86(10):1075-86.
71. Junghanss C, Boeckh M, Carter RA, et al. Incidence and outcome of cytomegalovirus
infections following nonmyeloablative compared with myeloablative allogeneic stem
cell transplantation, a matched control study. Blood. 2002;99(6):1978-85.
72. Miller W, Flynn P, McCullough J, Balfour HH Jr, Goldman A, Haake R, et al.
Cytomegalovirus infection after bone marrow transplantation: an association with
acute graft-v-host disease. Blood. 1986;67(4):1162-7.
73. Stachel D, Kirby K, Corey L, Boeckh M. CMV viral load as predictor for transplant-
related mortality in the era of pre-emptive therapy. Bone Marrow
Transplant. 2008;41:S46.
74. Hakki M, Riddell SR, Storek J, et al. Immune reconstitution to cytomegalovirus after
allogeneic hematopoietic stem cell transplantation: impact of host factors, drug
therapy, and subclinical reactivation. Blood. 2003;102:3060-3067.
75. Marchesi F, Pimpinelli F, Dessanti ML, Gumenyuk S, Palombi F, Pisani F, Romano A,
Spadea A, Maschio M, Ensoli F, Mengarelli A. Evaluation of risk of symptomatic
cytomegalovirus reactivation in myeloma patients treated with tandem autologous
stem cell transplantation and novel agents: a single-institution study. Transpl Infect

95